A Limited Role of p53 on the Ability of a Hexane Fraction of American Ginseng to Suppress Mouse Colitis

Poudyal, Deepak; Cui, Xiangli; Le, Phuong Mai; Davis, Tia; Hofseth, Anne B.; Jin, Yu; Chumanevich, Alexander A.; Wargovich, Michael J.; Nagarkatti, Mitzi; Windust, Anthony; Hofseth, Lorne J.

doi:10.1155/2012/785739

Cited by 11 publications

(16 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TUNEL labeling was performed as we have done previously [ 25 ]. Briefly, TK6 cells were incubated in 0.1% NBCS supplemented RPMI-1640 media for 24 hrs.…”

Section: Methodsmentioning

confidence: 99%

Repurposing the anti-malarial drug, quinacrine: new anti-colitis properties

et al. 2016

Self Cite

View full text Add to dashboard Cite

BackgroundUlcerative colitis (UC) is a chronic inflammatory bowel disease that is associated with an increased risk of colorectal cancer in 8-10 years after disease onset. Current colitis treatment strategies do not offer a cure for the disease, but only treat the symptoms with limited success and dangerous side-effects. Also, there is no preventive treatment for either UC or colorectal cancer. Quinacrine is an anti-malarial drug with versatile use in the treatment of diseases involving inflammatory response such as rheumatoid arthritis and lupus erythematosus. It also has putative anti-cancer effect. Quinacrine's anti-inflammatory, anti-oxidant properties, and anti-tumorigenic properties make it a potential small molecule preventive agent for both UC and associated colorectal cancer.ResultsThere were obvious changes in the CDI, histology, and inflammatory load in quinacrine-treated groups in a dose and time dependent manner in both models of UC, induced by chemical or haptenating agent.MethodsWe tested quinacrine at two different doses as a colitis treatment agent in two mouse models of UC - the dextran sulfate sodium and oxazolone. The clinical disease index (CDI), histological changes of the colon, levels of inflammatory markers (Cox-2, iNOS, p53) and overall health vitals were evaluated.ConclusionsWe demonstrate that quinacrine successfully suppresses colitis without any indication of toxicity or side-effects in two mouse models of UC.

show abstract

“…TUNEL labeling was performed as we have done previously [ 25 ]. Briefly, TK6 cells were incubated in 0.1% NBCS supplemented RPMI-1640 media for 24 hrs.…”

Section: Methodsmentioning

confidence: 99%

Repurposing the anti-malarial drug, quinacrine: new anti-colitis properties

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…From Bioassay guided fractionation of AG, we have recently shown that a Hexane fraction of AG (HAG) is a potent anti-oxidant and anti-cancer agent [24], [25]. To date, only limited anti-cancer studies of lipophilic extracts of AG have been carried out, and these studies are mostly focused on anti-proliferative and cytotoxic effects [26], [27], [28], [29].…”

Section: Introductionmentioning

confidence: 99%

A Key Role of microRNA-29b for the Suppression of Colon Cancer Cell Migration by American Ginseng

Poudyal

Cui

et al. 2013

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Metastasis of colon cancer cells increases the risk of colon cancer mortality. We have recently shown that American ginseng prevents colon cancer, and a Hexane extract of American Ginseng (HAG) has particularly potent anti-inflammatory and anti-cancer properties. Dysregulated microRNA (miR) expression has been observed in several disease conditions including colon cancer. Using global miR expression profiling, we observed increased miR-29b in colon cancer cells following exposure to HAG. Since miR-29b plays a role in regulating the migration of cancer cells, we hypothesized that HAG induces miR-29b expression to target matrix metalloproteinase-2 (MMP-2) thereby suppressing the migration of colon cancer cells. Results are consistent with this hypothesis. Our study supports the understanding that targeting MMP-2 by miR-29b is a mechanism by which HAG suppresses the migration of colon cancer cells.

show abstract

“…The American Ginseng (AG) Panax quinquefolius extract has been described previously in detail by our laboratory [14], as well, as we have recently described the generation of the Hexane fraction of AG (HAG) [44]. …”

Section: Methodsmentioning

confidence: 99%

Looking for the best anti-colitis medicine: A comparative analysis of current and prospective compounds

et al. 2016

Self Cite

View full text Add to dashboard Cite

Ulcerative colitis (UC) is a chronic lifelong inflammatory disorder of the colon, which, while untreated, has a relapsing and remitting course with increasing risk of progression toward colorectal cancer. Current medical treatment strategies of UC mostly focus on inhibition of the signs and symptoms of UC to induce remission and prevent relapse of disease activity, minimizing the impact on quality of life, but not affecting the cause of disease. To date, however, there is no single reliable treatment agent and/or strategy capable of effectively controlling colitis progression throughout the patient's life without side effects, remission, or resistance. Taking into consideration an urgent need for the new colitis treatment strategies, targets and/ or modulators of inflammation, we have tested current and prospective compounds for colitis treatment and directly compared their anti-colitis potency using a dextran sulfate sodium (DSS) mouse model of colitis. We have introduced a composite score -a multi-parameters comparison tool -to assess biological potency of different compounds.

show abstract

A Limited Role of p53 on the Ability of a Hexane Fraction of American Ginseng to Suppress Mouse Colitis

Cited by 11 publications

References 48 publications

Repurposing the anti-malarial drug, quinacrine: new anti-colitis properties

Repurposing the anti-malarial drug, quinacrine: new anti-colitis properties

A Key Role of microRNA-29b for the Suppression of Colon Cancer Cell Migration by American Ginseng

Looking for the best anti-colitis medicine: A comparative analysis of current and prospective compounds

Contact Info

Product

Resources

About